Pembrolizumab has a molecular weight of 149 kDa and nivolumab has a molecular weight of 145 kDa, suggesting that PD-1/PD-L1 axis-mediated antibody inhibition occurs outside the tumour. Here, CD274 is linked to neoplasm.